This article from Genetherapylive is dated today, but...

This article from Genetherapylive is dated today, but importantly confirms that progress is still on track for first quarter next year for the IND & trials

"CyCART-19 is an investigational CAR T-cell therapy that is derived from the placenta and cryopreserved. The allogenic, off-the shelf agent is in development for the treatment of B-cell malignancies and targets CD19. Celularity plans to file an investigational new drug application for the agent in the first quarter of 2022 and commence phase 1 of the study in the first quarter of 2022.1"

(link to full story below)

https://www.genetherapylive.com/view/celularity-imugene-collaboration-car-t-solid-tumors

This comment from Bob Hariri sums up the potential

“We found that Imugene’s technology and our technology created a unique opportunity to apply what we know about placental T-cells that can be engineered to express a CAR and their long-term applications in areas [such as] solid tumors, which up to this point have been unexploited.”



Capt